UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2016

Commission file number: 001-36621

FOAMIX PHARMACEUTICALS LTD.
(Translation of registrant's name into English)

2 Holzman Street, Weizmann Science Park
Rehovot, Israel
(Address of principal executive office)
_____________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   
 
Form 20-F     Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
 

 
CONTENTS

This report on Form 6-K of the registrant consists of a press release issued by the registrant on November 15, 2016, announcing the registrant’s third quarter financial results for the period ending September 30, 2016, and including the registrant’s unaudited condensed consolidated balance sheets, statements of operations and statements of cash flow, attached hereto and incorporated by reference herein.

The information contained in this Form 6-K is incorporated by reference into (i) the registration statement on Form S-8 (number 333-199486) of the registrant, filed with the Securities and Exchange Commission, and (ii) the registration statement on Form F-3 (333-207543) of the registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit

99.1
Press release issued by the registrant on November 15, 2016 announcing the registrant’s third quarter financial results for the period ending September 30, 2016.
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
FOAMIX PHARMACEUTICALS  LTD.
(Registrant)
 
 
 
By:
/s/ Ilan Hadar
 
 
 
Name: Ilan Hadar
 
 
 
Title: Chief Financial Officer 
 
 
Date: November 15, 2016
 
2

 
Foamix Pharmaceuticals (NASDAQ:FOMX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Foamix Pharmaceuticals Charts.
Foamix Pharmaceuticals (NASDAQ:FOMX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Foamix Pharmaceuticals Charts.